CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome
British Journal of Clinical Pharmacology2015Vol. 80(6), pp. 1388–1398
Citations Over TimeTop 16% of 2015 papers
Ellen A. Cannady, Jeffrey G. Suico, Ming‐Dauh Wang, Stuart Friedrich, Jessica Rehmel, Stephen J. Nicholls, Kathryn A. Krueger
Abstract
Taken together, the extent of CYP-mediated DDI with the potential clinical dose of evacetrapib is weak and clinically important DDIs are not expected to occur in patients taking concomitant medications.
Related Papers
- → Prevalence and pattern of diabetic dyslipidemia in Indian type 2 diabetic patients(2009)42 cited
- → Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now?(2011)26 cited
- → Abstract: S3-7 HUMAN CETP DEFICIENCY AND CETP INHIBITION(2009)
- → Abstract: 1060 UPDATE ON CETP INHIBITION(2009)
- Analysis of dyslipidemia for staffs at government departments of some towns in Wuling mountains(2013)